Lowest-Rated StocksLowest-RatedPositive News SentimentPositive NewsNASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis $1.46 -0.04 (-2.67%) Closing price 04:00 PM EasternExtended Trading$1.46 0.00 (0.00%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Pliant Therapeutics Stock (NASDAQ:PLRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pliant Therapeutics alerts:Sign Up Key Stats Today's Range$1.44▼$1.5150-Day Range$1.34▼$1.8652-Week Range$1.10▼$16.10Volume310,763 shsAverage Volume638,485 shsMarket Capitalization$89.63 millionP/E RatioN/ADividend YieldN/APrice Target$8.19Consensus RatingHold Company Overview Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems. The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). In preclinical studies, Pliant has also advanced research-stage integrin modulators aimed at addressing fibrosis in diabetic nephropathy and other indications with high unmet medical need. Founded in 2015, Pliant has built its research and development capabilities around translational biomarkers and validated preclinical models. The company’s clinical programs are conducted through multi‐center studies in North America, with plans to expand patient enrollment into additional geographies as part of global development efforts. Leadership at Pliant is led by President and Chief Executive Officer Vikram Shembekar, who brings extensive biopharmaceutical development experience. The management team combines expertise in clinical development, regulatory strategy and commercialization planning, positioning the company to advance its integrin-targeted pipeline toward potential regulatory approvals and eventual patient access.AI Generated. May Contain Errors. Read More Pliant Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScorePLRX MarketRank™: Pliant Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 180th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingPliant Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 1 buy rating, 12 hold ratings, and no sell ratings.Upside PotentialPliant Therapeutics has a consensus price target of $8.19, representing about 460.8% upside from its current price of $1.46.Amount of Analyst CoveragePliant Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Pliant Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($3.64) to ($3.72) per share.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pliant Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.95% of the float of Pliant Therapeutics has been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pliant Therapeutics has recently increased by 1.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.73 Percentage of Shares Shorted5.95% of the float of Pliant Therapeutics has been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pliant Therapeutics has recently increased by 1.20%, indicating that investor sentiment is decreasing. News and Social Media3.8 / 5News SentimentN/A News SentimentPliant Therapeutics has a news sentiment score of 1.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pliant Therapeutics this week, compared to 3 articles on an average week.Search Interest4 people have searched for PLRX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pliant Therapeutics' insider trading history. Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLRX Stock News HeadlinesNeedham Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)August 21, 2025 | theglobeandmail.comCiti Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)August 21, 2025 | theglobeandmail.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.September 23 at 2:00 AM | Traders Agency (Ad)Pliant Therapeutics price target raised to $1.70 from $1.50 at CitiAugust 11, 2025 | msn.comPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)July 24, 2025 | theglobeandmail.comPliant Therapeutics Provides Update on BEACON-IPFJune 27, 2025 | globenewswire.comAlnylam, Pliant among stocks yet to face Q2 catalysts: Wells FargoJune 7, 2025 | msn.comSee More Headlines PLRX Stock Analysis - Frequently Asked Questions How have PLRX shares performed this year? Pliant Therapeutics' stock was trading at $13.17 at the beginning of the year. Since then, PLRX stock has decreased by 88.9% and is now trading at $1.46. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced its quarterly earnings data on Thursday, August, 7th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.09. When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Pliant Therapeutics' major shareholders? Pliant Therapeutics' top institutional investors include JPMorgan Chase & Co. (3.19%), Redmile Group LLC (2.66%), Peapod Lane Capital LLC (1.46%) and Monaco Asset Management SAM (1.14%). Insiders that own company stock include Bernard Coulie, Keith Lamont Cummings, Eric Lefebvre, Hans Hull and Mike Ouimette. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings8/07/2025Today9/23/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PLRX CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Pliant Therapeutics$8.19 High Price Target$38.00 Low Price Target$1.50 Potential Upside/Downside+460.8%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($3.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$210.30 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.45% Return on Assets-55.66% Debt Debt-to-Equity Ratio0.14 Current Ratio12.99 Quick Ratio12.99 Sales & Book Value Annual Sales$1.58 million Price / Sales56.73 Cash FlowN/A Price / Cash FlowN/A Book Value$5.00 per share Price / Book0.29Miscellaneous Outstanding Shares61,390,000Free Float57,459,000Market Cap$89.63 million OptionableOptionable Beta1.43 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:PLRX) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.